Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting

Am J Cardiol. 2003 Jun 1;91(11):1346-9. doi: 10.1016/s0002-9149(03)00327-8.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / pharmacology*
  • Arteritis / blood
  • Arteritis / etiology
  • Arteritis / prevention & control
  • Biomarkers / blood
  • C-Reactive Protein / drug effects*
  • Coronary Stenosis / therapy*
  • Coronary Vessels / metabolism
  • Coronary Vessels / surgery
  • Eptifibatide
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / pharmacology*
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Peptides / pharmacology*
  • Platelet Aggregation Inhibitors / pharmacology
  • Prospective Studies
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Stents / adverse effects

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Immunoglobulin Fab Fragments
  • Interleukin-6
  • Peptides
  • Platelet Aggregation Inhibitors
  • Receptors, Interleukin-1
  • C-Reactive Protein
  • Eptifibatide
  • Abciximab